Esperion Therapeutics develops and commercializes therapies for cardiometabolic and rare/orphan diseases, with a commercial focus on oral, once-daily, non-statin LDL-C treatments for patients at risk for cardiovascular disease. Company news commonly covers NEXLETOL bempedoic acid data, CLEAR Outcomes analyses, dyslipidemia guideline developments, financial results, business updates, and material agreements.
Esperion's news also reflects portfolio expansion through its completed acquisition of Corstasis Therapeutics and Enbumyst bumetanide nasal spray, an FDA-approved loop diuretic for edema associated with congestive heart failure and hepatic or renal disease in adults. Additional recurring topics include ACLY biology, product commercialization, pipeline work in Primary Sclerosing Cholangitis and renal diseases, and governance or capital-structure matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.